UNSPSC 51183300: Antidiabetic and hyperglycemic dipeptidyl peptidase-4 inhibitors

This classification denotes compounds that suppress incretins degradation by blocking dipeptidyl-peptidase iv action, thus correcting defective insulin and glucagon secretion, thus the term ANTIDIABETIC AND HYPERGLYCEMIC DIPEPTIDYL PEPTIDASE-4 INHIBITORS.

UNSPSC 51183300 Antidiabetic and hyperglycemic dipeptidyl peptidase-4 inhibitors, a Class code, names a specific pharmaceutical product category — DPP-4 inhibitor drugs used to manage Type 2 diabetes and hyperglycemia. State and local governments procure these medications primarily through Medicaid and public health programs serving eligible beneficiaries, and through state employee health plans and municipal employee benefit programs that cover pharmacy services. The medications are typically purchased in bulk by health plans, pharmacy benefit managers contracted to state agencies, and centralized procurement offices serving multi-entity healthcare systems or correctional health services. Issuing bodies include state health departments, state Medicaid agencies, departments of corrections (which maintain on-site pharmacies for incarcerated populations), county health authorities, and municipal employee benefits offices.

The source provided contains no recent state or local contract opportunities tagged to this code and does not support geographic characterization, issuing-body concentration, or representative solicitation examples. Activity under UNSPSC 51183300 may be minimal at the posted-opportunity level; many pharmaceutical procurements by state Medicaid programs and health plans are negotiated directly with vendors or awarded through standing cooperative purchasing agreements rather than advertised solicitations, and thus do not appear in public RFP, IFB, or ITB notice streams.